Abstract 100P
Background
Colon cancer (CC) is one of the most common malignancies in the world. In this study, we investigated the involvement of a mitosis related chromosome condensation protein NCAPG in tumor progression, and in the prognosis of human CC.
Methods
The patient cohort in this study consisted of 123 CC cases from 2009 to 2013, documenting pathologic and clinical factors, as well as clinical outcomes. Immunohistochemistry and immunoblotting were employed to examine the NCAPG expression in 123 pairs of normal and CC tissues and 7 colon cells. Based on the expression of NCAPG, one CC cell with high NCAPG level was chosen for knockdown of NCAPG expression. The effect of NCAPG knockdown on the growth, migration and invasion of NCAPG-manipulated CC cells was examined.
Results
NCAPG protein overexpression was observed in 88 patients and was significantly correlated with depth of invasion, distant metastasis, staging, and poor disease-free and overall survival. Multivariate Cox regression analysis showed that NCAPG overexpression is an indenpendent prognostic marker for CC. Furthermore, NCAPG expression was elevated in several CC cells. In vitro experiments indicated that NCAPG knockdown inhibited CC cell growth, migration and invasion.
Conclusions
This study suggests that overexpression of NCAPG can be a useful marker for predicting the outcome of CC patients and that NCAPG targeting can represent a potential modality for treating CC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Chi Mei Medical Center.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87P - Negative to positive lymph node ratio-prognostic marker of survival in node positive rectal cancer
Presenter: Pavan Jonnada
Session: Poster display session
Resources:
Abstract
88P - The Sidra LUMC advanced colon cancer NGS cohort
Presenter: Wouter Hendrickx
Session: Poster display session
Resources:
Abstract
89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection
Presenter: Masaaki Noguchi
Session: Poster display session
Resources:
Abstract
90P - High MICB expression confers prognostic benefit in colorectal cancer
Presenter: Shanchao Yu
Session: Poster display session
Resources:
Abstract
91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Presenter: Chien-Hsin Chen
Session: Poster display session
Resources:
Abstract
92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma
Presenter: Vipin Goel
Session: Poster display session
Resources:
Abstract
93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
Presenter: Yijiao Chen
Session: Poster display session
Resources:
Abstract
94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis
Presenter: Michio Nakamura
Session: Poster display session
Resources:
Abstract
95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases
Presenter: Ye Wei
Session: Poster display session
Resources:
Abstract
96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases
Presenter: Nicola Taylor
Session: Poster display session
Resources:
Abstract